All In Biotech

Drug Trial Radar · NCT05983250

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jan 10, 2024

Primary completion

Jun 30, 2026

Study completion Oct 30, 2028

Sponsor

Lead sponsor
Tenax Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Medpace, Inc.; Northwestern University
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).

Conditions

  • Pulmonary Hypertension

Interventions

  • TNX-103Drug

    oral levosimendan 1 mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Six-minute walk distanceTime frame: 12 weeks

Locations

42 sites in 2 countries. Site status is shown where the registry gives one.

  • Tenax Investigational Site

    Tucson, Arizona

  • Tenax Investigational Site

    La Jolla, California

  • Tenax Investigational Site

    Los Angeles, California

  • Tenax Investigational Site

    Los Angeles, California

  • Tenax Investigational Site

    Sacramento, California

  • Tenax Investigational Site

    San Francisco, California

  • Tenax Investigational Site

    Torrance, California

  • Tenax Investigational Site

    Jacksonville, Florida

  • Tenax Investigational Site

    Winter Haven, Florida

  • Tenax Investigational Site

    Atlanta, Georgia

  • Tenax Investigational Site

    Chicago, Illinois

  • Tenax Investigational Site

    Chicago, Illinois

  • Tenax Investigational Site

    Galesburg, Illinois

  • Tenax Investigational Site

    Indianapolis, Indiana

  • Tenax Investigational Site

    Indianapolis, Indiana

  • Tenax Investigational Site

    Louisville, Kentucky

  • Tenax Investigational Site

    Boston, Massachusetts

  • Tenax Investigational Site

    Minneapolis, Minnesota

  • Tenax Investigational Site

    Rochester, Minnesota

  • Tenax Investigational Site

    St Louis, Missouri

  • Tenax Investigational Site

    Omaha, Nebraska

  • Tenax Investigational Site

    New York, New York

  • Tenax Investigational Site

    New York, New York

  • Tenax Investigational Site

    Rochester, New York

  • Tenax Investigational Site

    Roslyn, New York

  • Tenax Investigational Site

    Durham, North Carolina

  • Tenax Investigational Site

    Greensboro, North Carolina

  • Tenax Investigational Site

    Cincinnati, Ohio

  • Tenax Investigational Site

    Columbus, Ohio

  • Tenax Investigational Site

    Pittsburgh, Pennsylvania

  • Tenax Investigational Site

    Providence, Rhode Island

  • Tenax Investigational Site

    Charleston, South Carolina

  • Tenax Investigational Site

    Columbia, South Carolina

  • Tenax Investigational Site

    Dallas, Texas

  • Tenax Investigational Site

    Dallas, Texas

  • Tenax Investigational Site

    Lubbock, Texas

  • Tenax Investigational Site

    Plano, Texas

  • Tenax Investigational Site

    Murray, Utah

  • Tenax Investigational Site

    Richmond, Virginia

  • Tenax Investigational Site

    Madison, Wisconsin

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.